Diakonos Oncology Secures $20 Million Financing to Advance Dendritic Cell Cancer Immunotherapy
Diakonos Oncology, a clinical-stage biotechnology company based in Houston focused on developing next-generation immunotherapies for aggressive cancers, has continued to strengthen its financial position through a series of significant funding milestones as it advances its lead therapy, dubodencel (DOC1021), through clinical development.
In May 2025, Diakonos Oncology closed a $20 million private placement financing structured through Simple Agreements for Future Equity. The funding was raised to accelerate the company’s Phase 2 clinical program in glioblastoma and to support expansion into additional cancer indications, including refractory melanoma. New investors participating in the round included Baylor College of Medicine and the Brain Tumor Investment Fund, along with the Buttonwood Titan QC Fund. Existing shareholders, including CEO Mike Wicks, also participated. In addition to its financial investment, Baylor College of Medicine provided in-kind services, contributing institutional research and clinical expertise to support Diakonos’s development efforts.
The $20 million financing is intended to act as a bridge to a planned Series A round expected to launch in the second half of 2025. The capital is being used to advance clinical trials of DOC1021 in glioblastoma, a highly aggressive brain cancer with limited treatment options, while also enabling exploration of the company’s dendritic cell platform in other hard-to-treat cancers. The financing provides Diakonos with extended operational runway as it prepares for larger institutional investment and later-stage development.
This latest round builds on earlier fundraising momentum. In August 2024, Diakonos Oncology completed an oversubscribed $11.4 million seed financing round led by Restem Group Inc.. The seed round was nearly three times oversubscribed, reflecting early investor confidence in the company’s scientific approach and clinical strategy. Proceeds from that round were used to establish manufacturing capabilities, strengthen the leadership team, and complete enrollment for the company’s Phase 1 glioblastoma study. The funding also positioned Diakonos to move efficiently into Phase 2 development.
DOC1021 is a double-loaded, patient-derived dendritic cell vaccine designed to stimulate a robust immune response against tumors. The therapy uses a patient’s own dendritic cells loaded with both tumor antigens and amplified tumor-derived mRNA, a combination intended to mimic viral infection and activate cytotoxic immune pathways without requiring genetic modification. This approach is designed to make the therapy both potent and broadly applicable within personalized cancer treatment.
Regulatory progress has further strengthened Diakonos’s investment profile. DOC1021 has received Fast Track designation from the U.S. Food and Drug Administration for both glioblastoma and pancreatic cancer programs, as well as Orphan Drug designation for glioblastoma. These designations are intended to facilitate faster development and review of therapies addressing serious conditions with unmet medical need.
Beyond equity and SAFE financings, Diakonos has also secured substantial non-dilutive funding. In December 2025, the company was awarded more than $7 million through a Product Development Research Grant from the Cancer Prevention and Research Institute of Texas. The grant supports advancement of DOC1021 into a Phase 1/2 clinical study for refractory melanoma, a cancer that no longer responds to standard treatments. The award placed Diakonos among a small group of recipients selected from a highly competitive applicant pool.
Taken together, Diakonos Oncology’s combination of private investment, institutional participation, and competitive grant funding reflects a diversified financing strategy aimed at reducing development risk while accelerating clinical progress. With multiple trials underway and additional indications planned, the company’s recent funding activity positions it to further validate its dendritic cell immunotherapy platform and prepare for its next stage of growth as it pursues new treatment options for patients with limited alternatives.
